Lupin Pharmaceuticals, Inc.

Select Language Afrikaans Albanian Arabic Armenian Azerbaijani Basque Belarusian Bulgarian Bengali Catalan Chinese (Simplified) Chinese (Traditional) Croatian Czech Danish Dutch English Estonian Filipino Finnish French Galician Georgian German Greek Gujarati Haitian Creole Hebrew Hindi Hungarian Icelandic Indonesian Irish Italian Japanese Javanese Kannada Khmer Korean Latvian Lithuanian Macedonian Malay Maltese Marathi Nepali Norwegian Persian Polish Portuguese Punjabi Romanian Russian Serbian Slovak Slovenian Spanish Swahili Swedish Tamil Telugu Thai Turkish Ukrainian Urdu Vietnamese Welsh Yiddish

This is a collection of articles archived for the excellence of their content.

2016

The Times of India, Aug 03 2016

Lupin arm buys 21 Japanese generics for Rs 1,000 crore

Drug major Lupin said it has agreed to buy a portfolio of 21generic brands from Japanese company Shionogi & Co for 15.4 billion yen ($150 million, or about Rs 1,000 crore), to strengthen its presence in the world's second largest pharmaceutical market.

By size, the $110-billion Japanese pharmaceutical market stands second only to the US, and is largely brand focused. The acquisition by Lupin's Japanese subsidiary Kyowa Pharmaceutical will be effective from December 1, 2016 and is subject to certain closing conditions and regulatory approvals, including the transfer of marketing authorization of products.

Lupin said the 21 products it is acquiring from Shionogi had sales of $90 million collectively in the year ended March, covering therapeutic areas such as central nervous system (CNS), oncology , cardiovascular and anti-infectives.

With this acquisition, Lupin will rank sixth among generic companies in Japan. At present, the company is ranked ninth and is a market leader in the CNS space with its AMEL brand, in addition to other generic pharmaceutical products in its portfolio.